The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
 
Shubham Pant
Consulting or Advisory Role - Ipsen; Janssen; Novartis; Zymeworks
Research Funding - 4D Pharma (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); bionte (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Elicio Therapeutics (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); NGM Biopharmaceuticals (Inst); Novartis (Inst); Pfizer (Inst); Purple Biotech (Inst); Rgenix (Inst); Xencor (Inst); Zymeworks (Inst)
 
Martin H. Schuler
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Novartis
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck Serono; Novartis; Roche; Sanofi; Takeda
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)
 
Gopa Iyer
Consulting or Advisory Role - Basilea; Bayer; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Olaf Witt
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Day One Therapeutics; Novartis; Roche
Research Funding - AstraZeneca; Bayer; Blueprint Medicines; Day One Therapeutics; GlaxoSmithKline; Janssen; Lilly O.; Loxo; Novartis; Roche
 
Toshihiko Doi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Rakuten Medical Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Janssen; Kaken Pharmaceutical; Kyowa Hakko Kirin; KYOWA KIRIN; MSD; Otsuka; Otsuka; PRA Health Sciences; Rakuten Medical; SHIONOGI; Sumitomo Dainippon; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Shukui Qin
No Relationships to Disclose
 
Josep Tabernero
Stock and Other Ownership Interests - Oniria Therapeutics
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Cardiff Oncology; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc; Tolremo
Other Relationship - Imedex/HMP; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
David A. Reardon
Honoraria - Advantagene; Agenus; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Deciphera; DelMar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Inovio Pharmaceuticals; Kintara Therapeutics; Kintara Therapeutics; KIYATEC; Medicenna; Merck; Merck KGaA; NEUVOGEN; Novocure; Oncorus; Regeneron; Sumitono Dainippon Pharma; Taiho Pharmaceutical; Taiho Pharmaceutical; Vivacitas Oncology; Y-mAbs Therapeutics
Consulting or Advisory Role - Advantagene; Agenus; Agios; Anheart Therapeutics; Bayer; Bristol-Myers Squibb; Delmar Pharmaceuticals; Ellipses Pharma; EMD Serono; Genenta Science; Imvax; Kintara Therapeutics; Kiyatec; Medicenna; Merck; Merck KGaA; Novocure; Oncorus; Regeneron; Taiho Pharmaceutical; Vivacitas Oncology
Research Funding - Acerta Pharma (Inst); Agenus (Inst); Celldex (Inst); EMD Serono (Inst); Enterome (Inst); Incyte (Inst); Omniox
 
Christophe Massard
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; BeiGene; Blueprint Medicines; BMS; Celgene; Debiopharm Group; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Faron Pharmaceuticals; Genentech/Roche; INNATE PHARMA; IPSEN; Janssen; Lilly; MSD; Novartis; ORION; Pfizer; PharmaMar; Sanofi; Taiho Pharmaceutical
 
Liam Welsh
No Relationships to Disclose
 
Iwona A. Lugowska
Honoraria - Agenus; Amgen; AstraZeneca; BeiGene; BMS; Celon Pharma; Cullinan Oncology; Jacobio; Janssen; Loxo; Macrogenics; Menarini; MSD; Pfizer; Rhizen Pharmaceuticals; ROCHE; Sanofi; Sanofi; Takeda
Consulting or Advisory Role - Boehringer Ingelheim
Research Funding - AGENUS (Inst); ROCHE (Inst)
Travel, Accommodations, Expenses - BMS
 
Omar Carranza
Honoraria - Bayer; Janssen; Merck; Novartis; Pfizer
Consulting or Advisory Role - Bayer; Janssen
Speakers' Bureau - Merck/Pfizer
 
Kim Stuyckens
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Johnson & Johnson
 
Huimin Liao
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
Travel, Accommodations, Expenses - Johnson & Johnson
 
Saltanat Najmi
Employment - Johnson & Johnson; Tmunity Therapeutics, Inc.
Stock and Other Ownership Interests - Johnson & Johnson
 
Constance Hammond
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
Research Funding - Janssen Research & Development
Travel, Accommodations, Expenses - Janssen Research & Development
Other Relationship - Janssen Research & Development
 
Shibu Thomas
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Spyros Triantos
Employment - Johnson & Johnson/Janssen
Stock and Other Ownership Interests - Johnson & Johnson/Janssen
 
Hussein Sweiti
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Janssen Research & Development
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Immunomedics; Janssen; Janssen (Inst); Loxo/Lilly; MSD Oncology; MSD Oncology (Inst); Pfizer/EMD Serono; Roche; Seagen; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Basilea (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Nektar (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen